Pancreatic cancer ranks 11th in incidence, and fifth in cancer deaths, with 29,000 affected annually.
Accurate estimates of the cost of pancreatic cancer are unavailable ; existing estimates are variable or not generalizable.
This paper presents detailed cost estimates for pancreatic cancer by service, age, and gender.
Direct and indirect societal costs are determined using a prevalence-based, human capital approach.
Total annual costs are $4.9 billion, (men : $3.0 billion, women : $1.9 billion).
Total direct costs are $881 million, with 71% ($627.1 M/$881.3 M) for those over 65 years.
Total hospital costs are 77% ($679.5 M/$881.3 M) of total direct costs.
Total indirect costs are $4.0 billion, with 63% ($2,518.43 M/$4,018 M) for those 45 to 64 years.
Mortality costs are $3.7 billion, 93% ($3,739 M/$4,018 M) of indirect costs.
This paper presents cost estimates that are precise and generalizable to the general population.
The surgical cost burden may be less than indicated previously, with most hospitalizations not including a major procedure, and average operating room costs accounting for only 9% ($1,045/$11,055) of hospital costs.
Women have significantly less cancer-directed surgery than men.
Mots-clés Pascal : Tumeur maligne, Pancréas, Homme, Epidémiologie, Etats Unis, Amérique du Nord, Amérique, Californie, Coût, Estimation, Corrélation, Critère âge, Sexe, Spécialité médicale, Appareil digestif pathologie, Pancréas pathologie
Mots-clés Pascal anglais : Malignant tumor, Pancreas, Human, Epidemiology, United States, North America, America, California, Costs, Estimation, Correlation, Age criterion, Sex, Medical specialty, Digestive diseases, Pancreatic disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0430917
Code Inist : 002B13C01. Création : 22/03/2000.